Dienogest Side Effects in Endometriosis Treatment
Dienogest 2 mg daily is generally well-tolerated with mostly mild-to-moderate side effects, but you must counsel patients about abnormal uterine bleeding (occurring in 55% of patients), bone mineral density loss, and monitor for serious but rare adverse events including depression and hemorrhagic shock.
Common Side Effects (Expect These)
The most frequent adverse reactions during dienogest therapy are:
- Abnormal uterine bleeding (55%) - This is the predominant side effect 1
- Amenorrhea (17%) - Secondary most common bleeding pattern change 1
- Headache (18.5%) - Generally mild-to-moderate intensity 2, 3
- Breast discomfort (<10%) - Low discontinuation rate 2
- Swelling (13%) - Typically not severe 1
- Depressed mood (<10%) - Monitor closely 2
- Acne (<10%) - Cosmetic concern but rarely leads to discontinuation 2
- Constipation (10.4%) - Manageable with conservative measures 3
Critical counseling point: Only 0.6% of patients discontinue due to bleeding irregularities despite the high incidence, indicating these patterns are generally tolerable 2. The bleeding pattern typically involves metrorrhagia (71.9% in long-term studies) but does not worsen with continued treatment duration 3.
Bone Mineral Density Effects (Monitor Long-Term)
Dienogest causes statistically significant but clinically modest decreases in lumbar spine BMD:
- Mean decrease of -1.6% at 24 weeks and -1.7% at 52 weeks in adult women 3
- No cumulative decrease beyond 52 weeks - the effect plateaus 3
- In adolescents (ages 12-18), mean decrease of -1.2% at 52 weeks with partial recovery to -0.6% six months after discontinuation 4
Clinical implication: Perform baseline DEXA scan and repeat every 24 months during long-term therapy 5. In one long-term study, 27.6% of patients developed osteopenia after extended use (>15 months) 5. This is particularly important in adolescents where bone accretion is critical 4.
Serious Adverse Events (Rare but Important)
While uncommon, you must be vigilant for:
- Depression - Screen at each visit, especially in patients with psychiatric history 1
- Hemorrhagic shock - Rare but reported; counsel on warning signs of severe bleeding 1
- Peritonitis (1%) - Consider if acute abdominal pain develops 1
- Decreased lumbar spine BMD - As detailed above 1
Side Effects More Common with Long-Term Use (>15 months)
Patients on extended therapy experience statistically higher rates of:
- Headaches - Increased frequency compared to short-term use 5
- Weight gain - More pronounced with prolonged treatment 5
- Libido reduction - Counsel proactively about sexual health 5
Uncommon Side Effects (<3%)
- Dysmenorrhea (0.2%)
- Dyspepsia (0.4%)
- Abdominal pain (1%)
- Urticaria (1%)
- Dyschezia, nausea, vomiting, back pain, anemia 1
Key Clinical Pearls
Estradiol levels remain in the low-physiological range during dienogest therapy, avoiding hypoestrogenic side effects seen with GnRH agonists 2. This explains the favorable tolerability profile compared to other hormonal treatments.
The safety profile does not worsen with treatment duration - adverse events remain stable in incidence and severity through 52-65 weeks of continuous use 2, 3.
Discontinuation rates are low - the favorable risk-benefit ratio is reflected in high treatment continuation rates across multiple studies 2.
Monitoring Strategy
- Baseline: Complete blood count, liver function, DEXA scan (especially if risk factors for osteoporosis)
- Every visit: Screen for depression, assess bleeding patterns, evaluate pain control
- Every 24 months: Repeat DEXA scan during long-term therapy 5
- Adolescents: More frequent BMD monitoring given critical bone development period 4
Special consideration for adolescents: The -1.2% BMD decrease with partial recovery after discontinuation requires individualized risk-benefit assessment, weighing pain control against bone health during this critical developmental window 4.